Vaccination strategies have failed to impact outcomes of cancer patients significantly! Why? We hypothesize that a primary reason for the failure of tumor vaccine strategies is because the magnitude of the antitumor immune response is insufficient to mediate tumor regression. Our own work, as well as that of others, has identified an approach that exploits the increased sensitivity of lymphocytes to respond to antigenic stimulae when they are placed under conditions of homeostasis-driven proliferation. We modeled this by vaccinating lymphopenic mice with a GM-CSF gene-modified melanoma cell line (D5-G6) following reconstitution with naive spleen cells. Subsequent examination of tumor vaccine-draining lymph node (TVDLN) T cells from reconstituted-lymphopenic mice (RLM) revealed a substantial increase in the frequency of activated T cells. Following in vitro activation these T cells contained a significantly elevated frequency of tumor- specific CD4 and CD8 T cells with augmented function in vitro and therapeutic efficacy in vivo. When reconstitution was performed using spleen cells from systemic B16BL6-D5 (D5) tumor-bearing mice (TBM), anti-tumor function was lost. However, depletion of CD25+ Treg cells from the spleen cells of TBM used for reconstitution led to recovery of tumor-specific function and therapeutic efficacy. This proposal builds on these findings, our extensive preclinical and clinical data to propose two clinical trials. The first, Aim 1, is a randomized Phase II trial that will directly translate our preclinical observations and determine whether lymphopenic patients vaccinated with autologous tumor and GM-CSF, and reconstituted with either autologous total PBMC or CD25-depleted PBMC will generate a higher frequency of tumor-specific IFN-gamma secreting T cells. This trial will allow us to """"""""pick the winner"""""""". The second trial, Aim 4, will use the winning strategy to induce tumor-specific T cells that will be harvested, activated and adoptively transferred back to the patient.
Aim 2 will characterize changes in the effector, effector/memory and central memory phenotype of tumor-specific T cells of patients treated on clinical trials proposed in aims 1 and 4.
Aim 3 will characterize the regulatory T cell population in the peripheral blood prior to and following induction of lymphopenia and reconstitution. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA119123-02
Application #
7237919
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Merritt, William D
Project Start
2006-06-01
Project End
2010-04-30
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
2
Fiscal Year
2007
Total Cost
$245,258
Indirect Cost
Name
Providence Portland Medical Center
Department
Type
DUNS #
099142093
City
Portland
State
OR
Country
United States
Zip Code
97213
Youn, Ui Joung; Sripisut, Tawanun; Miklossy, Gabriella et al. (2017) Bioactive polyprenylated benzophenone derivatives from the fruits extracts of Garcinia xanthochymus. Bioorg Med Chem Lett 27:3760-3765
Church, Sarah E; Jensen, Shawn M; Twitty, Christopher G et al. (2011) Multiple vaccinations: friend or foe. Cancer J 17:379-96
Butterfield, Lisa H; Palucka, A Karolina; Britten, Cedrik M et al. (2011) Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 17:3064-76
Jensen, Shawn M; Maston, Levi D; Gough, Michael J et al. (2010) Signaling through OX40 enhances antitumor immunity. Semin Oncol 37:524-32
Petrausch, Ulf; Poehlein, Christian H; Jensen, Shawn M et al. (2009) Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr Mol Med 9:673-82
LaCelle, Michael G; Jensen, Shawn M; Fox, Bernard A (2009) Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res 15:6881-90
Walker, Edwin B; Haley, Daniel; Petrausch, Ulf et al. (2008) Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization. Clin Cancer Res 14:5270-83
Ruttinger, Dominik; van den Engel, Natasja K; Winter, Hauke et al. (2007) Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response. J Transl Med 5:43
Ruttinger, Dominik; Hatz, Rudolf A; Jauch, Karl-Walter et al. (2007) Current immunotherapeutic strategies in lung cancer. Surg Oncol Clin N Am 16:901-18, x
van den Engel, Natasja K; Winter, Hauke; Ruttinger, Dominik et al. (2006) Characterization of immune responses in gastric cancer patients: a possible impact of H. pylori to polarize a tumor-specific type 1 response? Clin Immunol 120:285-96